Organogenesis Holdings INC

Organogenesis Holdings Inc. held its 2026 Annual Meeting of Stockholders, approving key proposals including director elections and auditor ratification.

Organogenesis Holdings Inc. announced record net product revenue for fiscal year 2025, reaching $563.0 million, despite anticipating a challenging first half of 2026 due to CMS payment reforms.

Organogenesis Holdings Inc. announced the appointment of Patrick McGuire as its new Chief Accounting Officer, effective February 18, 2026.

Organogenesis Holdings Inc. has extended leases for its critical Canton, MA manufacturing and R&D facilities, securing operations through at least 2032 with an option to 2034.

Organogenesis Holdings Inc. reported record third-quarter 2025 financial results, driven by strong product revenue growth, and subsequently raised its full-year 2025 guidance.

Organogenesis Holdings Inc. announced its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, did not achieve statistical significance for its primary pain reduction endpoint, despite numerical improvement.

Organogenesis Holdings Inc. reports a 31% increase in Q3 2025 net product revenue, driven by new products, but its second Phase 3 ReNu trial for knee OA did not achieve statistical significance for its primary endpoint.

Organogenesis Holdings Inc. reported a significant decline in Q2 2025 revenue and a widened net loss, primarily driven by regulatory ambiguity in the advanced wound care market.

Organogenesis Holdings Inc. experienced a 21% decrease in net revenue for the first quarter of 2025, primarily due to the delayed implementation of local coverage determinations (LCDs) and subsequent customer behavior changes.

Organogenesis Holdings announced its third-quarter 2024 financial results, highlighted by a 6% increase in net revenue and a significant $130 million investment through a preferred stock offering.

Organogenesis Holdings Inc. reported a net loss for the second quarter of 2024, alongside revenue growth and strategic adjustments, including an impairment charge and a software write-down.

Organogenesis Holdings Inc. reports a modest revenue increase in Q1 2024, alongside a net loss, while managing costs and navigating regulatory challenges.

Organogenesis Holdings Inc. reported a significant increase in net product revenue for fiscal year 2025, driven by Advanced Wound Care products, while navigating evolving Medicare reimbursement policies and advancing its ReNu BLA submission.

Organogenesis Holdings Inc. files an amendment to its 2024 annual report on Form 10-K to include Part III information regarding directors, executive officers, corporate governance, and executive compensation.

Organogenesis Holdings Inc. files its 10-K report for the fiscal year ended December 31, 2024, detailing its financial performance and strategic plans for growth in the regenerative medicine and tissue innovation markets.

Organogenesis Holdings Inc. reported its full year 2023 financial results, highlighting revenue of $433.1 million and a net income of $4.9 million.

Chief Commercial Officer Brian Grow exercised options for 958 shares of Class A Common Stock shortly before their expiration date.

Organogenesis Holdings Inc. Director Arthur S Leibowitz purchased 5,000 shares of Class A Common Stock at $2.681 per share.

Organogenesis Holdings Inc.'s Vice President of Strategy, Robert Cavorsi, disposed of 700 shares of Class A Common Stock to cover tax liabilities.

Organogenesis Holdings Inc. Director Glenn H. Nussdorf reported the sale of 200,000 Class A Common Stock shares for approximately $1.027 million.

Glenn H. Nussdorf, a Director and 10% owner of Organogenesis Holdings Inc., sold 300,000 shares of Class A Common Stock over three days in late November 2025.

Organogenesis Holdings Inc. Director and 10% owner Glenn Nussdorf reported recent stock transactions and resolved a Section 16(b) short-swing profit violation.

Organogenesis Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 23, 2025, to vote on director re-election, executive compensation, a Nasdaq proposal, and auditor ratification.

Organogenesis Holdings Inc. is holding its 2024 Annual Meeting of Stockholders on June 20, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and ratification of the independent accounting firm.

Glenn H. Nussdorf and associated trusts updated their beneficial ownership in Organogenesis Holdings Inc. to 9.7% following the dissolution of a prior shareholder group.

A group of significant shareholders in Organogenesis Holdings Inc., including Alan A. Ades, Albert Erani, Glenn H. Nussdorf, and Dennis Erani, have formally dissolved their 'group' status under SEC Rule 13d-5, transitioning to individual beneficial ownership reporting following the termination of their Controlling Stockholders' Agreement.

A group of significant shareholders, including Alan A. Ades and Albert Erani, have filed Amendment No. 9 to their Schedule 13D, detailing updated beneficial ownership percentages and recent share transfers, notably a large gift for estate planning purposes.

A group of significant shareholders, including Alan A. Ades and Albert Erani, have filed an Amendment No. 8 to their Schedule 13D, updating their beneficial ownership in Organogenesis Holdings Inc. and disclosing recent share transfers and a company repurchase.

Soleus Capital Master Fund and its affiliates reported a beneficial ownership of 7.9% in Organogenesis Holdings Inc., holding 9,985,951 shares as of December 31, 2025.

First Light Asset Management and Mathew P. Arens report increased beneficial ownership in Organogenesis Holdings, Inc., now holding 6.55% of common stock.

Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have reported a collective beneficial ownership of 9.9% in Organogenesis Holdings Inc., totaling 12,484,876 shares.